<unk>  is available as a prodrug<unk>  hydrochloride, and is metabolized in the liver to form the pharmacologically active compound<unk> at. Formation of<unk> at is caused by hydrolysis of an ethyl ester group.<unk>  is incompletely absorbed after oral administration, and its bioavailability is low. The long pharmacokinetic half-life and persistent ACE inhibition of<unk>  allows once-daily administration.<unk>  is highly lipophilic, and is in the same hydrophobic range as quinapril, benazepril, and ramipril. Lipophilic ACE inhibitors are able to penetrate membranes more readily, thus tissue ACE may be a target in addition to plasma ACE. A significant reduction in tissue ACE (lung, myocardium, aorta, and kidney) activity has been shown after<unk>  use. It has additional PDE4-inhibiting effects.
Moexipril
Racecadotril
Spirapril
Ramipril
Pravastatin
Lovastatin
Rosuvastatin
Ganirelix